

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 June 2005 (30.06.2005)


PCT

(10) International Publication Number
WO 2005/058250 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number:
PCT/US2004/042301
- (22) International Filing Date:
17 December 2004 (17.12.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/530,149 17 December 2003 (17.12.2003) US
60/553,991 17 March 2004 (17.03.2004) US
60/622,954 28 October 2004 (28.10.2004) US
- (71) Applicant (for all designated States except US): **GUILFORD PHARMACEUTICALS INC.** [US/US]; 6611 Tributary Street, Baltimore, MD 21224 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SLUSHER, Barbara, S.** [US/US]; 7424 Longfield Drive, Kingsville, MD 21087 (US). **WOZNIAK, Krystyna** [GB/US]; 422 Fox Catcher Road, Bel Air, MD 21015 (US).
- (74) Agent: **RIVARD, Paul, M.**; Banner & Witcoff, Ltd., 11th Floor, 1001 G. Street, N.W., Washington, DC 20001-4597 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: METHODS OF ADMINISTERING WATER-SOLUBLE PRODRUGS OF PROPOFOL FOR EXTENDED SEDATION



(57) Abstract: A method of administering a prodrug of propofol, preferably O-phosphonoxyethyl propofol disodium salt, comprises the oral, intragastric, or intrainestinal administration of the prodrug in amounts sufficient to induce or maintain a generalized anesthetized state, a conscious sedated state, or to treat insomnia, anxiety, nausea, vomiting, pruritus, epilepsy, and a range of pain syndromes and other medical conditions.



Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.